{"meshTagsMajor":["Drug Resistance, Neoplasm"],"meshTags":["Brain Neoplasms","Chemokine CCL2","Drug Resistance, Neoplasm","Humans","Organ Specificity","PTEN Phosphohydrolase","Protein Kinase Inhibitors","Small Molecule Libraries","Tumor Microenvironment"],"meshMinor":["Brain Neoplasms","Chemokine CCL2","Humans","Organ Specificity","PTEN Phosphohydrolase","Protein Kinase Inhibitors","Small Molecule Libraries","Tumor Microenvironment"],"genes":["TRK Inhibitors","LMNA","NTRK1","TRK","LMNA","NTRK1"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Two recent studies validate the LMNA-NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA-NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker-based clinical trials across cancer subtypes.","title":"Tracking Down Response and Resistance to TRK Inhibitors.","pubmedId":"26747892"}